Home/Pipeline/Nerivio

Nerivio

Acute Treatment of Migraine

ApprovedCommercial

Key Facts

Indication
Acute Treatment of Migraine
Phase
Approved
Status
Commercial
Company

About Theranica

Theranica is a commercial-stage digital therapeutics company pioneering remote electrical neuromodulation (REN) for migraine. Its FDA-authorized and CE-marked Nerivio device is a prescription wearable for acute migraine treatment in adolescents and adults, offering a drug-free alternative. The company is expanding its technology platform into other neurological conditions, such as chronic migraine prevention and other pain disorders. Backed by venture capital, Theranica operates as a private entity, commercializing its device in the US and internationally.

View full company profile

About Theranica

Theranica is a commercial-stage digital therapeutics company pioneering remote electrical neuromodulation (REN) for migraine. Its FDA-authorized and CE-marked Nerivio device is a prescription wearable for acute migraine treatment in adolescents and adults, offering a drug-free alternative. The company is expanding its technology platform into other neurological conditions, such as chronic migraine prevention and other pain disorders. Backed by venture capital, Theranica operates as a private entity, commercializing its device in the US and internationally.

View full company profile

Therapeutic Areas

Other Acute Treatment of Migraine Drugs

DrugCompanyPhase
Elismetrep (K-304)KallyopePhase 2
RizaFilm® (RizaPort®)Gensco PharmaApproved/Pre-launch
ONZETRA XsailCurrax PharmaceuticalsApproved
TREXIMETCurrax PharmaceuticalsApproved
NVI-100Nuvie BioPhase 1
gammaCoreelectroCoreCommercial